| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | 0.023 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |